[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,874,314
  • Shares Outstanding, K 64,915
  • Annual Sales, $ 4,268 M
  • Annual Income, $ -356,150 K
  • EBIT $ 1,405 M
  • EBITDA $ 2,101 M
  • 60-Month Beta 0.32
  • Price/Sales 3.82
  • Price/Cash Flow 15.44
  • Price/Book 3.39

Options Overview Details

View History
  • Implied Volatility 30.16% (+1.20%)
  • Historical Volatility 30.28%
  • IV Percentile 6%
  • IV Rank 10.94%
  • IV High 65.31% on 11/14/25
  • IV Low 25.84% on 11/24/25
  • Expected Move (DTE 19) 12.20 (4.99%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 121
  • Volume Avg (30-Day) 427
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 6,068
  • Open Int (30-Day) 6,870
  • Expected Range 232.34 to 256.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $5.60
  • Number of Estimates 6
  • High Estimate $6.10
  • Low Estimate $5.35
  • Prior Year $6.99
  • Growth Rate Est. (year over year) -19.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
240.63 +1.62%
on 08/14/26
266.38 -8.20%
on 08/25/26
-12.38 (-4.82%)
since 07/28/26
3-Month
220.74 +10.78%
on 06/18/26
266.38 -8.20%
on 08/25/26
+9.16 (+3.89%)
since 05/28/26
52-Week
123.88 +97.40%
on 09/15/25
266.38 -8.20%
on 08/25/26
+118.41 (+93.88%)
since 08/28/25

Most Recent Stories

More News
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

DUBLIN , Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior...

JAZZ : 244.54 (-2.61%)
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

DUBLIN , Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"),...

JAZZ : 244.54 (-2.61%)
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line...

JAZZ : 244.54 (-2.61%)
3 Profitable Stocks with Questionable Fundamentals

3 Profitable Stocks with Questionable Fundamentals

HLF : 12.43 (+0.65%)
JAZZ : 244.54 (-2.61%)
PLUS : 87.28 (-0.43%)
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy

JAZZ : 244.54 (-2.61%)
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

JAZZ : 244.54 (-2.61%)
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

JAZZ : 244.54 (-2.61%)
Jazz: Q2 Earnings Snapshot

Jazz: Q2 Earnings Snapshot

JAZZ : 244.54 (-2.61%)
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

– Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) –

JAZZ : 244.54 (-2.61%)
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect

Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect

JAZZ : 244.54 (-2.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 254.77
2nd Resistance Point 252.71
1st Resistance Point 248.62
Last Price 244.54
1st Support Level 242.47
2nd Support Level 240.41
3rd Support Level 236.32

See More

52-Week High 266.38
Last Price 244.54
Fibonacci 61.8% 211.94
Fibonacci 50% 195.13
Fibonacci 38.2% 178.31
52-Week Low 123.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.